Providing Hope

Through support for academic and industry research, FARE promotes the development of new therapies and offers hope for effective treatments.

FARE is the world’s largest private source of food allergy research funding, providing more than $90 million in research support to date. Our investment sheds light on the causes, diagnosis, prevention and treatment of this life-threatening disease.

New Initiatives

  • More than 3,000 patients joined the FARE Patient Registry. Launched in May, this password-protected database empowers food allergy patients or their legal representatives to help drive food allergy research forward by sharing their deidentified (anonymous) medical histories with the members of the research community.
  • Three exceptional scientists received 2017 FARE Investigators in Food Allergy Awards, an investment of more than $1 million to support innovative new research. This multiyear research grant program attracts gifted early and mid-career investigators to the field of food allergy. Dr. Edda Fiebigeris assessing whether inhibiting enzymes active during allergic reactions might lead to better outcomes for oral immunotherapy. Dr. Robert Anthony is examining how adding sugar molecules to allergy-mediating IgE antibodies might promote or limit allergic reactions. Dr. Stephane Eisenbarthis studying an inherited predisposition to food allergies to better understand the development of food allergies in the general population.

Ongoing Projects

  • The FARE Clinical Network (FCN) expanded to include 29 leading food allergy centers. This pioneering collaboration among centers of excellence coordinates best practices infood allergy research and clinical care. FCN centers offer state-of-the-art food allergy diagnosis, management and clinical trials to patients and families across the country.
  • Two recipients of 2015 FARE Investigator in Food Allergy Awards made key discoveries. Dr. Erik Wambre identified a type of immune cell found only in individuals with allergies. Dr. Michiko Oyoshi demonstrated that mothers exposed to a food while pregnant and nursing produce food-specific antibodies that are transferred to the newborn during breastfeeding and protect the newborn against allergies to the food.
  • Immunotherapy trials to treat peanut, tree nut and wheat allergies received continued support.
  • Two meetings convened by FARE were attended by researchers, government officials, industry representatives and food allergy advocates from around the world. At the fifth Research Retreat, recipients of the 2015 and 2017 FARE Investigator in Food Allergy Awards were among the presenters who reported their research plans and progress to more than 100 participants. During the first Partners in Action Day hosted by the International Food Allergy & Anaphylaxis Alliance, patient representatives from 19 countries shared their insights with regulators, drug and food manufacturers, scientists, clinicians and others.
  • FARE’s Outcomes Research Advisory Board (ORAB), a partnership of patient representatives and others brought patient perspectives to food allergy research. Regional ORAB groups identified patient priorities for research and developed novel ways to communicate this information to key stakeholders.